Author

M. Brito

Observed names: M.E. Brito, Marcelli Brito

Observed institutions: Instituto Português de Oncologia Francisco Gentil, Instituto Nacional de Câncer - INCA

ORCID: 0000-0003-1501-5478

Observed ORCID: 0000-0003-1501-5478

OpenAlex ID: A5090185060

VP04.08: Performance of the IOTA ADNEX model in distinguishing types of ovarian malignancy: a Portuguese multicentre study

2021 · A.L. Borges, M.E. Brito, et al. · Ultrasound in Obstetrics and Gynecology

Predictors of effectiveness of the use of steroidal aromatase inhibitors after progression on non-steroidal aromatase inhibitors in advanced breast cancer patients

2016 · M.M. Ulrich de Menezes Pereira dos Santos, C. Cardoso, et al. · Annals of Oncology

Tumor-infiltrating Lymphocytes are Independent Favorable Prognostic Indicator in 17-year Disease-Free Survival in Lymph Node-Negative Triple-Negative Breast Cancer Patient

2016 · Ana Eisenberg, Leila Chimelli, et al. · Journal of Advances in Medicine and Medical Research

1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study

2015 · A. Ferreira, A. Palha, et al. · European Journal of Cancer

Works count: 4

Citation count:

H-index:

I10-index: